Search

Displaying results 2261 - 2270 of 7600 in total
  1. Drug

    Imetelstat

    go.drugbank.com/drugs/DB14909
    ApprovedInvestigational

    [A187838] Standard therapy for anemia in patients with MDS involves the use of erythropoiesis-stimulating agents (e.g. … [A187838] Imetelstat received FDA approval in June 2024 for use in certain patients with MDS who have transfusion-dependent anemia and are unable to use ESAs.[L50883,L50888]

  2. Drug

    Nevirapine

    go.drugbank.com/drugs/DB00238
    ApprovedInvestigational

    A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS.

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  3. Drug

    CYNK-001

    go.drugbank.com/drugs/DB15722
    Investigational

    CYNK-001 is a novel allogenic off-the-shelf natural killer (NK) cell therapy originating from human placental CD34+ hematopoietic stem cells and enriched with CD56+/CD3-.

  4. Drug

    Promethazine

    go.drugbank.com/drugs/DB01069
    ApprovedInvestigational

    [A189901] Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.

    Categories: Antihistamines for Topical Use, Antihistamines for Systemic Use
  5. Drug

    Amobarbital

    go.drugbank.com/drugs/DB01351
    ApprovedIllicit

    A barbiturate with hypnotic and sedative properties (but not antianxiety). Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmac...

  6. Drug

    Valoctocogene roxaparvovec

    go.drugbank.com/drugs/DB15561
    ApprovedInvestigationalWithdrawn

    [L43282,A252807] Valoctocogene roxaparvovec was approved by EMA in September 2022 and is indicated for the treatment of severe hemophilia A. It is not approved for use in the United States. … Valoctocogene roxaparvovec is an adeno-associated virus serotype 5 (AAV5) based gene therapy vector that expresses the B-domain deleted SQ form of human coagulation factor VIII (hFVIII-SQ).

  7. Drug

    Selinexor

    go.drugbank.com/drugs/DB11942
    ApprovedInvestigational

    Other chemotherapies for multiple myeloma include [lenalidomide] and [dexamethasone], [thalidomide], and may include [melphalan] if the patient is not eligible for transplant. … [L7123] Selinexor was also granted accelerated approval for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that have gone through at least 2 lines of

  8. Drug

    Delamanid

    go.drugbank.com/drugs/DB11637
    ApprovedInvestigational

    Spontaneous resistance to delamanid was observed during treatment, where mutation in one of the 5 F420 coenzymes responsible for bioactivation of delamanid contributes to this effect [L1407]. … Emergence of multidrug-resistant and extensively drug-resistant tuberculosis creates clinical challenges for patients, as the disease is associated with a higher mortality rate and insufficient therapeutic

    Categories: Antiinfectives for Systemic Use, Drugs for Treatment of Tuberculosis
  9. Drug

    Cocaine

    go.drugbank.com/drugs/DB00907
    ApprovedIllicitInvestigational

    It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat.

  10. Drug

    Tislelizumab

    go.drugbank.com/drugs/DB14922
    ApprovedInvestigational

    [L50346] It has subsequently been approved for additional cancers in the US and EU. [L49349] … This approval was based on positive results demonstrated in the RATIONALE 302 study, where an 8.6-month median overall survival rate was observed for tislelizumab treatment compared to 6.3-month for chemotherapy